Xaciato FDA Approval History
Last updated by Judith Stewart, BPharm on Dec 8, 2021.
FDA Approved: Yes (First approved December 7, 2021)
Brand name: Xaciato
Generic name: clindamycin phosphate
Dosage form: Vaginal Gel
Previous Name: DARE-BV1
Company: Daré Bioscience, Inc.
Treatment for: Bacterial Vaginosis
Xaciato (clindamycin phosphate) is a topical lincosamide antibacterial for the vaginally-administered treatment of bacterial vaginosis in female patients 12 years of age and older.
- Xaciato is a thermosetting bioadhesive hydrogel formulation of clindamycin phosphate 2% for the treatment of bacterial vaginosis via a single application. It is a viscous liquid designed to undergo solution to gel (sol-to-gel) transition using body temperature as the trigger. This property allows the product to be more easily directed to the site of infection.
- Xaciato is administered once intravaginally as a single dose at any time of the day.
- Xaciato may cause serious adverse reactions including Clostridioides difficile-associated diarrhea. Common adverse reactions include vulvovaginal candidiasis and vulvovaginal discomfort.
Development timeline for Xaciato
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.